目的 探讨康复新液联合泮托拉唑钠肠溶胶囊治疗反流性食管炎的临床疗效。方法 选取2016年7月-2018年4月辽河油田总医院收治的96例反流性食管炎患者作为研究对象，随机将患者分为对照组（48例）和治疗组（48例）。对照组口服泮托拉唑钠肠溶胶囊，40 mg/次，1次/d；治疗组在对照组治疗的基础上口服康复新液，10 mL/次，3次/d。两组患者疗程均为8周。观察两组患者的临床疗效，同时比较两组治疗前后的内镜分级情况、临床症状评分和血清胃泌素（GAS）、血浆胃动素（MOT）水平。结果 治疗后，治疗组的总有效率为93.8%，显著高于对照组的72.9%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组内镜分级均明显改善（P<0.05）；且治疗后，治疗组0级例数显著多于对照组，Ⅱ级、Ⅲ级例数显著少于对照组（P<0.05）。治疗后，两组烧心、反酸、胸骨后疼痛、反食和总评分均显著下降（P<0.05）；且治疗后治疗组临床症状评分均显著低于对照组（P<0.05）。治疗后，两组血清GAS、MOT水平均显著升高（P<0.05）；且治疗后治疗组的血清GAS、MOT水平均显著高于对照组（P<0.05）。结论 康复新液联合泮托拉唑钠肠溶胶囊治疗反流性食管炎的疗效显著，可有效改善患者临床症状，具有一定的临床推广应用价值。

Objective To investigate the clinical curative effect of Kangfuxin Liquid combined with Pantoprazole Sodium Enteric-coated Capsules in treatment of reflux esophagitis.Methods Patients (96 cases) with reflux esophagitis in General Hospital of Liaohe Oilfield from July 2016 to April 2018 were divided into control (48 cases) and treatment (48 cases) groups. Patients in the control group were po administered with Pantoprazole Sodium Enteric-coated Capsules, 40 mg/time, once daily. Patients in the treatment group were po administered with Kangfuxin Liquid, 10 mL/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the endoscopic grading, clinical symptom scores, GAS and MOT levels in two groups before and after treatment were compared.Results After treatment, the clinical efficacy in the treatment group was 93.8%, which was significantly higher than 72.9% in the control group, and there were differences between two groups (P<0.05). After treatment, the endoscopic grading was significantly improved in two groups (P<0.05). After treatment, the numbers of grade 0 cases in the treatment group were significantly higher than that in the control group, and the number of grade Ⅱ and Ⅲ cases was significantly lower than that in the control group (P<0.05). After treatment, the heartburn, acid regurgitation, retrosternal pain, food regurgitation, and total scores in two groups were significantly decreased (P<0.05). After treatment, the clinical symptom scores in the treatment group were lower than those in the control group (P<0.05). After treatment, the levels of GAS and MOT in two groups were significantly increased (P<0.05). After treatment, the levels of GAS and MOT in the treatment group were higher than those in the control group, with significant difference between two groups (P<0.05).Conclusion Kangfuxin Liquid combined with Pantoprazole Sodium Enteric-coated Capsules has significant clinical efficacy in treatment of reflux esophagitis, can effectively improve the clinical symptoms of patients, which has a certain clinical application value.